When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. TCH (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/TCH_(chemotherapy)

   TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References

3. Triple-negative breast cancer - Wikipedia

   en.wikipedia.org/wiki/Triple-negative_breast_cancer

   Triple-negative is sometimes used as a surrogate term for basal-like. [2] Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers.

4. Chemotherapy regimen - Wikipedia

   en.wikipedia.org/wiki/Chemotherapy_regimen

   breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP

5. AstraZeneca's breast cancer drug combination fails in late ...

   www.aol.com/news/astrazenecas-breast-cancer-drug...

   The trial, known as CAPItello-290, was testing whether the drug combination improved overall survival in patients with inoperable or metastatic triple-negative breast cancer versus the older and ...

6. Docetaxel - Wikipedia

   en.wikipedia.org/wiki/Docetaxel

   Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]

7. Breast cancer classification - Wikipedia

   en.wikipedia.org/wiki/Breast_cancer_classification

   Conversely, triple negative cancer (i.e. no positive receptors), lacking targeted treatments, now has a comparatively poor prognosis. [42] [43] Androgen receptor is expressed in 80-90% of ER+ breast cancers and 40% of "triple negative" breast cancers. Activation of androgen receptors appears to suppress breast cancer growth in ER+ cancer while ...